Increased  ||| S:0 E:10 ||| JJ
bioavailability  ||| S:10 E:26 ||| NN
of  ||| S:26 E:29 ||| IN
hydrocortisone  ||| S:29 E:44 ||| JJ
dissolved  ||| S:44 E:54 ||| NN
in  ||| S:54 E:57 ||| IN
a  ||| S:57 E:59 ||| DT
cream  ||| S:59 E:65 ||| NN
base  ||| S:65 E:70 ||| NN
The  ||| S:70 E:74 ||| DT
aim  ||| S:74 E:78 ||| NN
of  ||| S:78 E:81 ||| IN
this  ||| S:81 E:86 ||| DT
study  ||| S:86 E:92 ||| NN
was  ||| S:92 E:96 ||| VBD
to  ||| S:96 E:99 ||| TO
compare  ||| S:99 E:107 ||| VB
vasoconstrictor  ||| S:107 E:123 ||| JJ
activity  ||| S:123 E:132 ||| NN
and ||| S:132 E:135 ||| CC
,  ||| S:135 E:137 ||| ,
by  ||| S:137 E:140 ||| IN
inference ||| S:140 E:149 ||| NN
,  ||| S:149 E:151 ||| ,
the  ||| S:151 E:155 ||| DT
clinical  ||| S:155 E:164 ||| JJ
anti-inflammatory  ||| S:164 E:182 ||| JJ
effectiveness  ||| S:182 E:196 ||| NN
of  ||| S:196 E:199 ||| IN
hydrocortisone  ||| S:199 E:214 ||| NN
in  ||| S:214 E:217 ||| IN
two  ||| S:217 E:221 ||| CD
different  ||| S:221 E:231 ||| JJ
formulations ||| S:231 E:243 ||| NNS
:  ||| S:243 E:245 ||| :
1 ||| S:245 E:246 ||| CD
%  ||| S:246 E:248 ||| NN
dissolved  ||| S:248 E:258 ||| VBN
hydrocortisone  ||| S:258 E:273 ||| JJ
cream  ||| S:273 E:279 ||| NN
and  ||| S:279 E:283 ||| CC
1 ||| S:283 E:284 ||| CD
%  ||| S:284 E:286 ||| NN
dispersed  ||| S:286 E:296 ||| VBD
hydrocortisone  ||| S:296 E:311 ||| JJ
cream ||| S:311 E:316 ||| NN
.  ||| S:316 E:318 ||| .
Moisturising  ||| S:318 E:331 ||| JJ
capacity  ||| S:331 E:340 ||| NN
and  ||| S:340 E:344 ||| CC
safety  ||| S:344 E:351 ||| NN
were  ||| S:351 E:356 ||| VBD
also  ||| S:356 E:361 ||| RB
determined ||| S:361 E:371 ||| VBN
.  ||| S:371 E:373 ||| .
Both  ||| S:373 E:378 ||| DT
topical  ||| S:378 E:386 ||| JJ
preparations  ||| S:386 E:399 ||| NNS
were  ||| S:399 E:404 ||| VBD
applied  ||| S:404 E:412 ||| VBN
without  ||| S:412 E:420 ||| IN
occlusion  ||| S:420 E:430 ||| NN
on  ||| S:430 E:433 ||| IN
forearms  ||| S:433 E:442 ||| VBG
twice  ||| S:442 E:448 ||| RB
daily  ||| S:448 E:454 ||| JJ
for  ||| S:454 E:458 ||| IN
5  ||| S:458 E:460 ||| CD
days ||| S:460 E:464 ||| NNS
.  ||| S:464 E:466 ||| .
An  ||| S:466 E:469 ||| DT
assessment  ||| S:469 E:480 ||| NN
of  ||| S:480 E:483 ||| IN
vasoconstriction  ||| S:483 E:500 ||| NN
was  ||| S:500 E:504 ||| VBD
performed  ||| S:504 E:514 ||| VBN
in  ||| S:514 E:517 ||| IN
a  ||| S:517 E:519 ||| DT
double-blinded  ||| S:519 E:534 ||| JJ
manner  ||| S:534 E:541 ||| NN
pretreatment  ||| S:541 E:554 ||| NNS
and  ||| S:554 E:558 ||| CC
then  ||| S:558 E:563 ||| RB
thrice  ||| S:563 E:570 ||| JJ
daily  ||| S:570 E:576 ||| JJ
for  ||| S:576 E:580 ||| IN
6  ||| S:580 E:582 ||| CD
days  ||| S:582 E:587 ||| NNS
and  ||| S:587 E:591 ||| CC
once  ||| S:591 E:596 ||| RB
7  ||| S:596 E:598 ||| CD
days  ||| S:598 E:603 ||| NNS
post-application ||| S:603 E:619 ||| JJ
,  ||| S:619 E:621 ||| ,
using  ||| S:621 E:627 ||| VBG
an  ||| S:627 E:630 ||| DT
objective  ||| S:630 E:640 ||| JJ
rating  ||| S:640 E:647 ||| NN
scale ||| S:647 E:652 ||| NN
.  ||| S:652 E:654 ||| .
For  ||| S:654 E:658 ||| IN
the  ||| S:658 E:662 ||| DT
dissolved  ||| S:662 E:672 ||| JJ
preparation  ||| S:672 E:684 ||| NN
only ||| S:684 E:688 ||| RB
,  ||| S:688 E:690 ||| ,
moisturising  ||| S:690 E:703 ||| JJ
capacity  ||| S:703 E:712 ||| NN
was  ||| S:712 E:716 ||| VBD
determined  ||| S:716 E:727 ||| VBN
by  ||| S:727 E:730 ||| IN
measurement  ||| S:730 E:742 ||| NN
of  ||| S:742 E:745 ||| IN
transepidermal  ||| S:745 E:760 ||| JJ
water  ||| S:760 E:766 ||| NN
loss  ||| S:766 E:771 ||| NN
( ||| S:771 E:772 ||| -LRB-
TEWL ||| S:772 E:776 ||| NNP
)  ||| S:776 E:778 ||| -RRB-
at  ||| S:778 E:781 ||| IN
0 ||| S:781 E:782 ||| CD
,  ||| S:782 E:784 ||| ,
2 ||| S:784 E:785 ||| CD
,  ||| S:785 E:787 ||| ,
4 ||| S:787 E:788 ||| CD
,  ||| S:788 E:790 ||| ,
6  ||| S:790 E:792 ||| CD
and  ||| S:792 E:796 ||| CC
24  ||| S:796 E:799 ||| CD
h ||| S:799 E:800 ||| NN
,  ||| S:800 E:802 ||| ,
and  ||| S:802 E:806 ||| CC
also  ||| S:806 E:811 ||| RB
by  ||| S:811 E:814 ||| IN
the  ||| S:814 E:818 ||| DT
measurement  ||| S:818 E:830 ||| NN
of  ||| S:830 E:833 ||| IN
water  ||| S:833 E:839 ||| NN
content  ||| S:839 E:847 ||| NN
at  ||| S:847 E:850 ||| IN
0  ||| S:850 E:852 ||| CD
and  ||| S:852 E:856 ||| CC
24  ||| S:856 E:859 ||| CD
h ||| S:859 E:860 ||| NNS
.  ||| S:860 E:862 ||| .
Safety  ||| S:862 E:869 ||| NNP
was  ||| S:869 E:873 ||| VBD
assessed  ||| S:873 E:882 ||| VBN
by  ||| S:882 E:885 ||| IN
repeat  ||| S:885 E:892 ||| NN
insult  ||| S:892 E:899 ||| NN
patch  ||| S:899 E:905 ||| NN
tests  ||| S:905 E:911 ||| NNS
( ||| S:911 E:912 ||| -LRB-
RIPT ||| S:912 E:916 ||| NNP
) ||| S:916 E:917 ||| -RRB-
.  ||| S:917 E:919 ||| .
In  ||| S:919 E:922 ||| IN
all ||| S:922 E:925 ||| DT
,  ||| S:925 E:927 ||| ,
10  ||| S:927 E:930 ||| CD
volunteers  ||| S:930 E:941 ||| NNS
completed  ||| S:941 E:951 ||| VBD
the  ||| S:951 E:955 ||| DT
vasoconstrictor  ||| S:955 E:971 ||| NN
and  ||| S:971 E:975 ||| CC
moisturising  ||| S:975 E:988 ||| JJ
studies ||| S:988 E:995 ||| NNS
,  ||| S:995 E:997 ||| ,
while  ||| S:997 E:1003 ||| IN
52  ||| S:1003 E:1006 ||| CD
completed  ||| S:1006 E:1016 ||| VBD
the  ||| S:1016 E:1020 ||| DT
RIPT ||| S:1020 E:1024 ||| NNP
.  ||| S:1024 E:1026 ||| .
For  ||| S:1026 E:1030 ||| IN
1 ||| S:1030 E:1031 ||| CD
%  ||| S:1031 E:1033 ||| NN
dissolved  ||| S:1033 E:1043 ||| VBN
hydrocortisone  ||| S:1043 E:1058 ||| JJ
cream  ||| S:1058 E:1064 ||| NN
and  ||| S:1064 E:1068 ||| CC
1 ||| S:1068 E:1069 ||| CD
%  ||| S:1069 E:1071 ||| NN
dispersed  ||| S:1071 E:1081 ||| VBD
hydrocortisone  ||| S:1081 E:1096 ||| JJ
cream ||| S:1096 E:1101 ||| NN
,  ||| S:1101 E:1103 ||| ,
respectively ||| S:1103 E:1115 ||| RB
,  ||| S:1115 E:1117 ||| ,
areas  ||| S:1117 E:1123 ||| NNS
under  ||| S:1123 E:1129 ||| IN
the  ||| S:1129 E:1133 ||| DT
blanching  ||| S:1133 E:1143 ||| JJ
curves  ||| S:1143 E:1150 ||| NN
were  ||| S:1150 E:1155 ||| VBD
1240  ||| S:1155 E:1160 ||| CD
and  ||| S:1160 E:1164 ||| CC
295 ||| S:1164 E:1167 ||| CD
;  ||| S:1167 E:1169 ||| :
total  ||| S:1169 E:1175 ||| JJ
scores  ||| S:1175 E:1182 ||| NNS
were  ||| S:1182 E:1187 ||| VBD
129.0  ||| S:1187 E:1193 ||| CD
and  ||| S:1193 E:1197 ||| CC
31.5 ||| S:1197 E:1201 ||| CD
;  ||| S:1201 E:1203 ||| :
summed  ||| S:1203 E:1210 ||| JJ
%  ||| S:1210 E:1212 ||| NN
total  ||| S:1212 E:1218 ||| JJ
possible  ||| S:1218 E:1227 ||| JJ
scores  ||| S:1227 E:1234 ||| NNS
were  ||| S:1234 E:1239 ||| VBD
161.3  ||| S:1239 E:1245 ||| CD
and  ||| S:1245 E:1249 ||| CC
39.4 ||| S:1249 E:1253 ||| CD
;  ||| S:1253 E:1255 ||| :
Tm ||| S:1255 E:1257 ||| NNP
/ ||| S:1257 E:1258 ||| CD
10  ||| S:1258 E:1261 ||| CD
mean  ||| S:1261 E:1266 ||| JJ
values  ||| S:1266 E:1273 ||| NNS
were  ||| S:1273 E:1278 ||| VBD
3.47  ||| S:1278 E:1283 ||| CD
and  ||| S:1283 E:1287 ||| CC
1.64 ||| S:1287 E:1291 ||| CD
.  ||| S:1291 E:1293 ||| .
The  ||| S:1293 E:1297 ||| DT
1 ||| S:1297 E:1298 ||| CD
%  ||| S:1298 E:1300 ||| NN
dissolved  ||| S:1300 E:1310 ||| VBN
hydrocortisone  ||| S:1310 E:1325 ||| JJ
cream  ||| S:1325 E:1331 ||| NN
was  ||| S:1331 E:1335 ||| VBD
found  ||| S:1335 E:1341 ||| VBN
to  ||| S:1341 E:1344 ||| TO
be  ||| S:1344 E:1347 ||| VB
statistically  ||| S:1347 E:1361 ||| RB
more  ||| S:1361 E:1366 ||| RBR
potent  ||| S:1366 E:1373 ||| JJ
than  ||| S:1373 E:1378 ||| IN
the  ||| S:1378 E:1382 ||| DT
1 ||| S:1382 E:1383 ||| CD
%  ||| S:1383 E:1385 ||| NN
dispersed  ||| S:1385 E:1395 ||| VBD
hydrocortisone  ||| S:1395 E:1410 ||| JJ
cream ||| S:1410 E:1415 ||| NN
.  ||| S:1415 E:1417 ||| .
Furthermore ||| S:1417 E:1428 ||| RB
,  ||| S:1428 E:1430 ||| ,
the  ||| S:1430 E:1434 ||| DT
1 ||| S:1434 E:1435 ||| CD
%  ||| S:1435 E:1437 ||| NN
dissolved  ||| S:1437 E:1447 ||| VBN
hydrocortisone  ||| S:1447 E:1462 ||| JJ
cream  ||| S:1462 E:1468 ||| NN
was  ||| S:1468 E:1472 ||| VBD
found  ||| S:1472 E:1478 ||| VBN
to  ||| S:1478 E:1481 ||| TO
be  ||| S:1481 E:1484 ||| VB
moisturising  ||| S:1484 E:1497 ||| VBN
compared  ||| S:1497 E:1506 ||| VBN
to  ||| S:1506 E:1509 ||| TO
no  ||| S:1509 E:1512 ||| DT
treatment ||| S:1512 E:1521 ||| NN
.  ||| S:1521 E:1523 ||| .
No  ||| S:1523 E:1526 ||| DT
adverse  ||| S:1526 E:1534 ||| JJ
events  ||| S:1534 E:1541 ||| NNS
were  ||| S:1541 E:1546 ||| VBD
observed ||| S:1546 E:1554 ||| VBN
.  ||| S:1554 E:1556 ||| .
A  ||| S:1556 E:1558 ||| DT
cream  ||| S:1558 E:1564 ||| NN
containing  ||| S:1564 E:1575 ||| VBG
1 ||| S:1575 E:1576 ||| CD
%  ||| S:1576 E:1578 ||| NN
dissolved  ||| S:1578 E:1588 ||| VBN
hydrocortisone  ||| S:1588 E:1603 ||| NN
exhibits  ||| S:1603 E:1612 ||| VBZ
greater  ||| S:1612 E:1620 ||| JJR
vasoconstrictor  ||| S:1620 E:1636 ||| JJ
activity  ||| S:1636 E:1645 ||| NN
than  ||| S:1645 E:1650 ||| IN
a  ||| S:1650 E:1652 ||| DT
cream  ||| S:1652 E:1658 ||| NN
containing  ||| S:1658 E:1669 ||| VBG
1 ||| S:1669 E:1670 ||| CD
%  ||| S:1670 E:1672 ||| NN
dispersed  ||| S:1672 E:1682 ||| VBD
hydrocortisone ||| S:1682 E:1696 ||| VBN
.  ||| S:1696 E:1698 ||| .
